Edition:
United States

Verona Pharma PLC (VRP.L)

VRP.L on London Stock Exchange

160.00GBp
3:45am EDT
Change (% chg)

5.00 (+3.23%)
Prev Close
155.00
Open
155.00
Day's High
--
Day's Low
--
Volume
15,838
Avg. Vol
76,680
52-wk High
200.00
52-wk Low
100.00

Chart for

About

Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company's product candidate, RPL554, is a... (more)

Overall

Beta: 0.49
Market Cap(Mil.): £162.78
Shares Outstanding(Mil.): 105.02
Dividend: --
Yield (%): --

Financials

  VRP.L Industry Sector
P/E (TTM): -- 243.17 32.94
EPS (TTM): -0.34 -- --
ROI: -- -7.30 12.79
ROE: -- -10.05 14.67

BRIEF-Verona Pharma Files For Mixed Shelf Of Upto $200 Mln

* VERONA PHARMA PLC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING Source text: (https://bit.ly/2rZgygq) Further company coverage:

May 22 2018

BRIEF-Verona Pharma Says Positive Top-Line Data From Phase 2B Trial Of RPl554

* VERONA PHARMA REPORTS POSITIVE TOP-LINE DATA FROM PHASE 2B CLINICAL TRIAL OF RPL554 FOR MAINTENANCE TREATMENT OF COPD

Mar 26 2018

BRIEF-Verona Pharma Says Positive Top-Line Data From Phase 2A Trial With Rpl554

* ‍REG-VERONA PHARMA REPORTS POSITIVE TOP-LINE DATA FROM PHASE 2A TRIAL WITH RPL554 IN CYSTIC FIBROSIS PATIENTS​

Mar 02 2018

BRIEF-Verona Pharma Expects To Report Top-Line Data From Phase 2b Trial Of Nebulized RPl554​ Early In Q2

* VERONA PHARMA PLC - ‍ANTICIPATES REPORTING TOP-LINE DATA FROM ITS PHASE 2B TRIAL EARLY IN Q2 OF 2018 FOR NEBULIZED RPL554​

Feb 13 2018

Earnings vs. Estimates